News

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

Inc.’s Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins, like customer expansion, key product launches, increased market share, and industry-defining accomplishments. Companies from a wide range of industries – such as technology, healthcare, finance, and retail – have been recognized for their success and positive influence on the business world. The full list can be found on Inc.com and in the upcoming winter print edition of Inc. magazine.

ivWatch has over 20 years of research and development under its belt since its founding, in its single-minded pursuit of improving IV safety globally, securing 69 patents for its technology in the process. Among the milestones the company has reached:

  • Over 300,000 patients monitored to date.
  • 9 million hours of patient monitoring to date.
  • Comparing January – September 2023 vs. 2024, single-use sensors sold increased 83%.
  • The company has expanded its footprint beyond the U.S. and the technology is now available in the U.K., Ireland, the Netherlands, Belgium, United Arab Emirates, Saudi Arabia, Australia, New Zealand, Canada, Qatar, Israel, and Kuwait.
  • >430% growth in product evaluations comparing 2023 completed evaluations to the evaluations completed in 2024, as of July. The evaluations completed in 2023 were located in only two countries (US and UK); as of January – July 2024, completed evaluations took place in 13 countries. An estimated total for evaluations to be completed by the end of 2024 would exceed the previous year 10 times.
  • Reached Top Ten in 2024 Startup World Cup Grand Finale.

“Being named to Inc.’s Best in Business list is a tremendous honor, and I want to thank everyone at ivWatch for their unwavering dedication toward growing our company and inventing an entirely new category with a solution we believe in that everyone around the world will one day need and benefit from,”  said ivWatch CEO Gary Warren. “We’re on a mission to solve one of the biggest problems in healthcare by reducing IV injuries, and this recognition belongs to the passionate ivWatch team who have started a movement along with our customers to keep patients safe from IV harm.”

Inc.’s Best in Business Awards are open to companies of all sizes and types, in all industries and locations. Public, private, nonprofit, subsidiary, U.S.-based, and international companies are all encouraged to apply. Inc. editors and reporters hand-review every application and select Best in Business honorees that, in each of the award categories, have had an outstanding influence on their communities, their industries, the environment, or society as a whole.

“For over 40 years, Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman.

For more information or to see the complete list, please visit inc.com/best-in-business.

 

Read more here.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or